Portfolio Update

4 July 2007 FINSBURY WORLDWIDE PHARMACEUTICAL TRUST PLC (the "Company") QUARTERLY STATEMENT OF INVESTMENTS In compliance with the Listing Rules - Chapter 21 Investment Entities (I)(ii), the Company discloses the following: * Investments valuing greater than 5% of the Company's gross assets comprise the following: Company Name Value of % of Total Investment at Portfolio Assets 30 June 2007 NOVARTIS CHF0.50 REGD 20,308,961 6.61 WYETH COM USD0.333 15,404,222 5.01 * The ten largest investments held by the Company comprise the following: Company Name Value of Investment % of Total at Portfolio Assets 30 June 2007 NOVARTIS CHF0.50 REGD 20,308,961 6.61 WYETH COM USD0.333 15,404,222 5.01 GEN-PROBE INC USD0.0001 14,755.874 4.80 GENENTECH INC COM STK USD0.02 NPV 13,868,208 4.51 AMGEN COM USD0.0001 13,418,078 4.36 JOHNSON & JOHNSON COM USD1 13,195,654 4.29 PFIZER INC COM USD0.05 12,915,468 4.20 TAKEDA PHARMACEUTICAL CO NPV 12,497,669 4.07 GENZYME CORP GENERAL DIVISION COM USD0.01 11,330,625 3.69 BIOGEN IDEC COM USD0.0005 11,325,417 3.68 - ENDS - For further information please contact: Mark Pope, Company Secretary Frostrow Capital LLP Telephone: 020 3 008 4913
UK 100

Latest directors dealings